CS
HARP

Credit Suisse’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Credit Suisse’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 4435
2022
Q2 		$0 Buy
+1
New +$26 ﹤0.01% 4498

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return

Credit Suisse's HARP Position: Q3 2022 in Review

Credit Suisse sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q3 2022, closing a stake of 1 share.

Credit Suisse first reported a position in HARP in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 52 funds tracked by Wall St. Rank hold HARP as of Q3 2022.

  • Credit Suisse reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 1 Harpoon Therapeutics, Inc. Common Stock share in Q3 2022.
  • Credit Suisse first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Harpoon Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 52 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.